Back to Multiple Sclerosis
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00668343

NCT00668343
Completed Phase 3

Who may be able to join

Who might be able to join this trial:

  • Your disability level is below 5 on a standard neurological scale used to measure how much a condition affects daily functioning (confirm with trial site)
  • You have had at least 1 attack or flare-up of your condition in the past year

Who may not be able to join:

  • You have more than 2 attacks or flare-ups during the time you are taking part in the study
  • You experience a complication related to the study drug during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Tehran University of Medical Sciences
Registry
clinicaltrials_gov
Start date
1 April 2005
Est. completion
1 March 2008

Where this trial is recruiting

Iran

Primary endpoints

attack number

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov